Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Neoadjuvant pembrolizumab improves event-free survival compared to adjuvant therapy in advanced resectable melanoma - Hospital Pharmacy EuropeHospital Pharmacy Europe

Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review - ScienceDirect

Advances in Adjuvant Therapy For Cutaneous Melanoma: Implications for Clinical Practice

Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy - Smithers - 2021 - ANZ Journal of Surgery - Wiley Online Library

Frontiers Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States

Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?

Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?

Neoadjuvant or adjuvant immunotherapy in melanoma stage iii

Recent Advances in the Treatment of Melanoma

Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma

Cancers, Free Full-Text